MedPath

MYLAN PHARMACEUTICALS PRIVATE LIMITED

🇮🇳India
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:4

Trial Phases

2 Phases

Phase 3:1
Not Applicable:2

Drug Approvals

47

CIMA_AEMPS:26
EMA:21

Drug Approvals

Sitagliptin / Metformin hydrochloride Mylan

Authorization Status
Authorised
Approval Date
Feb 16, 2022
EMA

Sugammadex Mylan

Authorization Status
Authorised
Approval Date
Nov 15, 2021
EMA

Abiraterone Mylan

Authorization Status
Authorised
Approval Date
Aug 20, 2021
EMA

Fingolimod Mylan

Authorization Status
Authorised
Approval Date
Aug 18, 2021
EMA

Azacitidine Mylan

Authorization Status
Authorised
Approval Date
Mar 27, 2020
EMA

Deferasirox Mylan

Authorization Status
Authorised
Approval Date
Sep 26, 2019
EMA

Deferasirox Mylan

Authorization Status
Authorised
Approval Date
Sep 26, 2019
EMA

Gefitinib Mylan

Authorization Status
Withdrawn
Approval Date
Sep 27, 2018
EMA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Not Applicable
2 (66.7%)
Phase 3
1 (33.3%)

A Bioequivalence Study Using Clinical Endpoint for Diclofenac Sodium Gel 1% in Osteoarthritis Knee"

Phase 3
Completed
Conditions
Osteoarthritis, Knee
Interventions
First Posted Date
2017-06-01
Last Posted Date
2022-03-03
Lead Sponsor
Mylan Pharmaceuticals Private Limited
Target Recruit Count
1220
Registration Number
NCT03172780
Locations
🇮🇳

Yashoda Hospital - Malakpet, Hyderabad, Andhra Pradesh, India

🇮🇳

Yashoda Hospital -Secunderabad, Secunderabad, Andhra Pradesh, India

🇮🇳

Yashoda Hospital -Somajiguda, Somajiguda, Andhra Pradesh, India

and more 29 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.